Endometriai Safety of Ultra-Low-Dose Estradiol Vaginal Tablets.

The article discusses a study which investigated the prevalence of endometrial hyperplasia and carcinoma after a 52-week treatment with ultra-low-dose 10-microgram 17Β-estradiol vaginal tablets. The study included 541 women with vaginal atrophy, who were given 17Β-estradiol vaginal tablets. Two cases of hyperplasia and carcinoma were reported in the women who underwent biopsy. Study authors concluded that ultra-low-dose vaginal estrogen is safe for the endometrium.